Need: Treatment delays due to symptoms & side effects, lack of understanding of treatment, and/or referral delays.
Solution:Helpsy Health provides 24/7 support to improve course of treatment by managing toxicity, mood decline, and facilitating access to other navigation resources.
Need: Poor patient education and lack of access to resources for symptom and side effect management.
Solution:Helpsy Health improves symptom and side effect management by 30-80% through 20,000+ self-guided recommendations and community programs in 25 areas.
Need: Outpatient services often create large gaps in communication, leading to loss in valuable Patient Reported Outcomes (PRO) data.
Solution:Tracking PROs through Helpsy Health’s platform to facilitate high quality, patient-centered care, using data sets that may be leveraged in multiple ways.
Need: Typical attrition rates for oncology trials are about 25% prior to the primary endpoint and go up to 40% by the end of study.
Solution:Helpsy Health creates a custom whole-health care plan (physical, emotional, social and support services) and engages the patient 24/7 by monitoring symptoms, answering questions, and escalating care as needed. Our service reduces participant dropout by 40% through 20,000+ self-guided recommendations and community programs in 25 areas.
Need: Toxicities and adverse events are among the main reasons for early participant withdrawal and trial failure - 70% of all toxicity related failures which occur preclinically constitute toxicological outcomes.
Solution:Helpsy Health improves symptom and side effect management by 30-80%. Our auto-triage system, escalation of care, and health monitoring reduce unmanaged toxicity and adverse events to improve trial success.
Need: Clinical trials are associated with high costs (up to $800 million to $1 billion per drug) and low success rates. Insufficient communication during trials leads to adverse events and non-adherence to the protocol, resulting in waste and redundancy.
Solution:Helpsy Health provides 24/7 support to manage adverse events and significantly reduce clinical trial costs associated with waste and redundancy.